 Four new product candidates under pre-clinical development announced; UCART20x22; the first allogeneic bi-specific CAR-T cell targeting B-cell malignancies, and three additional product candidates for solid tumors UCARTMESO targeting Mesothelin, UCARTMUC1 targeting Mucin 1, UCARTFAP targeting Cancer Associated Fibroblasts 